the scale of the impact we could have
More than 300,000 kids are diagnosed with cancer each year worldwide.
And all of them need better treatments than they have now.
Pediatric cancer diagnoses increase by nearly 1% per year, with no signs of slowing down. Each year, more and more kids will need access to child-friendly treatments. Every time we fund a better treatment, we don’t just benefit one child or one family, we provide a path to recovery for every child who will ever have that cancer… from now until forever.
YOU CAN MAKE A DIFFERENCE
Each new cancer treatment has the power to save kids’ lives.
In just 17 years, we’ve funded more than 150+ research grants that have resulted in 60+ of child-first treatments becoming available, and reaching kids. Every breakthrough improves not only the lives of today’s patients, but every child diagnosed tomorrow.
Beau
ependymoma
Eloise
retinoblastoma
155
Grants Funded
Each Recipient Is Selected by Our Medical Advisory Board of the Nation’s Leading Pediatric Oncologists.
Aidan
neuroblastoma
60+
Treatments Developed
We Fund Research Across All Types and Subtypes of Childhood Cancer.
Mira
acute myeloid leukemia
Ber
neuroblastoma
Taylor
neuroblastoma and leukemia
21,500+
Grassroots Events
Supporters Have Hosted Grassroots Fundraisers in All 50 States and More Than 30 Countries.
Max
neuroblastoma
$25M+
Granted to Research
We Fund Groundbreaking Research at the Nation’s Top Pediatric Cancer Hospitals.
Ivy
neuroblastoma
Beau
ependymoma
Eloise
retinoblastoma
155
Grants Funded
Each Recipient Is Selected by Our Medical Advisory Board of the Nation’s Leading Pediatric Oncologists.
Aidan
neuroblastoma
60+
Treatments Developed
We Fund Research Across All Types and Subtypes of Childhood Cancer.
Mira
acute myeloid leukemia
Ber
neuroblastoma
Taylor
neuroblastoma and leukemia
21,500+
Grassroots Events
Supporters Have Hosted Grassroots Fundraisers in All 50 States and More Than 30 Countries.
Max
neuroblastoma
$25M+
Granted to Research
We Fund Groundbreaking Research at the Nation’s Top Pediatric Cancer Hospitals.
Ivy
neuroblastoma
our investments
155 Grants Funded
How We Drive Innovation in Kids’ Cancer Treatments
| Year | Amount | Hospital | Researcher | Grant Name | Category | Type of Cancer | Subtype |
|---|---|---|---|---|---|---|---|
| 2025 | $200,000.00 | Children's Hospital of Philadelphia | Dr. Kristopher Bosse | GPC2 CARs and dinutuximab: synergizing dual antigen targeting and adaptive and innate antitumor immunity via blocking the GD2-siglec-7 inhibitory axis in neuroblastoma | Solid and Bone Cancers | Neuroblastoma | |
| 2025 | $100,000.00 | Children's Hospital of Philadelphia | Dr. John Maris | Functional characterization and armoring of peptide-centric CAR T cells to enhance efficacy | Solid and Bone Cancers | Neuroblastoma | |
| 2025 | $200,000.00 | Children's Hospital of Philadelphia | Dr. Yael Mossé | Identifying and Targeting Epigenomic Mechanisms of Resistance in neuroblastoma | Solid and Bone Cancers | Neuroblastoma | |
| 2025 | $225,500.00 | Children's Oncology Group | |||||
| 2025 | $200,000.00 | Dana-Farber Cancer Institute | Dr. Yana Pikman | Targeting MAT2A for novel T-cell acute lymphoblastic leukemia therapy | Blood Cancer | Leukemia | Acute Lymphoblastic Leukemia |
| 2025 | $200,000.00 | Seattle Children's Hospital | Dr. Jack Brzezinski | Enhanced Wilms tumor diagnosis, risk stratification, and surveillance through cell free DNA methylation | Solid and Bone Cancers | Wilms Tumor | |
| 2025 | $100,000.00 | Seattle Children's Hospital | Dr. James Olson | Antigen Assimilating Multispecific T Cell Engagers (MTEs) for the Treatment of diffuse midline glioma (DMG) | Brain Tumors | Diffuse Midline Glioma | |
| 2025 | $200,000.00 | Seattle Children's Hospital | Dr. Nicholas Vitanza | B7-H3-targeting myeloid cells against diffuse midline glioma | Brain Tumors | Diffuse Midline Glioma | |
| 2025 | $200,000.00 | St. Jude Children's Research Hospital | Dr. Alejandro Gutierrez | Defining and Targeting PI3Kgamma-Mediated Asparaginase Resistance in T-cell acute lymphoblastic leukemia | Blood Cancer | Leukemia | Acute Lymphoblastic Leukemia |
| 2025 | $200,000.00 | Texas Children's Cancer Center | Dr. David Steffan | Armored GPC3-CAR T cells for children with treatment refractory atypical teratoid rhabdoid tumors | Brain Tumors | Atypical Teratoid Rhabdoid Tumors | |
| 2025 | $100,000.00 | UCSF Benioff Children's Hospital | Dr. Ross Okimoto | Exploiting DNA repair mechanisms to overcome CIC-DUX4 sarcoma | Solid and Bone Cancers | Sarcoma | |
| 2025 | $200,000.00 | UCSF Benioff Children's Hospital | Dr. Elliot Stieglitz | Preclinical Evaluation of Direct RAS Inhibition in juvenile myelomonocytic leukemia | Blood Cancer | Leukemia | Juvenile Myelomonocytic Leukemia |
| 2024 | $224,000.00 | Children's Oncology Group | |||||
| 2024 | $200,000.00 | Dana-Farber Cancer Institute/Jimmy Fund | Dr. A. Thomas Look | Developing cytokine-armed CAR-NKT immunotherapy for neuroblastoma | Solid and Bone Cancers | Neuroblastoma | |
| 2024 | $200,000.00 | Memorial Sloan Kettering Cancer Center | Dr. Jason Lewis | Radiotherapeutic Targeting of Developmental Mutators in Childhood Solid Tumors As a Prelude to a New Clinical Trial for Children with neuroblastomas and Other DLL3 Solid Tumors | Solid and Bone Cancers | Neuroblastoma | |
| 2024 | $200,000.00 | Seattle Children's Hospital/Fred Hutchinson Cancer Research Center | Dr. Mignon Loh | Testing an Immunotherapy Drug/Molecule for Dual Recognition and Attachment to CD19 and CD33 Markers on MPAL Cancer Cells | Blood Cancer | Leukemia | |
| 2024 | $125,000.00 | St. Jude Children's Research Hospital | Dr. Sara Federico | HuNB803: A Safety Run-in and Phase 2 Randomized Trial of Chemoimmunotherapy Administered With or Without N-803, A Novel IL-15 Superagonist, for the Treatment of Patients With Relapsed or Refractory neuroblastoma | Solid and Bone Cancers | Neuroblastoma | |
| 2024 | $125,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Carl Allen | Defining cell(s) of origin and clinical risk in Langerhans cell histiocytosis | Blood Cancer | Langerhans cell histiocytosis | |
| 2024 | $350,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Meenakshi Hegde | Multi-center clinical testing of autologous HER2 CAR T cells and its synergy with surgical resection in recurrent ependymoma | Brain Tumors | Ependymoma | |
| 2024 | $200,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Leonid Metelitsa | Developing cytokine-armed CAR-NKT immunotherapy for neuroblastoma | Solid and Bone Cancers | Neuroblastoma | |
| 2024 | $200,000.00 | UCSF Benioff Children's Hospital | Dr. Arun Wiita | Optimized anti-CD70 CAR-NK cells for the treatment of pediatric acute myeloid leukemia | Blood Cancer | Leukemia | Acute myeloid leukemia (AML) |
| 2023 | $200,000.00 | Children's Hospital of Philadelphia | Dr. John Maris | Functional characterization and armoring of peptide-centric CAR T cells to enhance efficacy | Solid and Bone Cancers | Neuroblastoma | |
| 2023 | $276,500.00 | Children's Oncology Group | |||||
| 2023 | $200,000.00 | Dana-Farber Cancer Institute/Jimmy Fund | Dr. Scott Armstrong | Targeting Chromatin Complexes in NUP98-rearranged AML | Blood Cancer | Leukemia | Acute myeloid leukemia (AML) |
| 2023 | $200,000.00 | Memorial Sloan Kettering Cancer Center | Dr. Nai-Kong Cheung | Enhancing the efficacy of GD2 Cancer Vaccine for high-risk neuroblastoma by augmenting seroconversion | Solid and Bone Cancers | Neuroblastoma | |
| 2023 | $200,000.00 | Seattle Children's Hospital/Fred Hutchinson Cancer Research Center | Dr. James Olson | Antigen Assimilating Multispecific T Cell Engagers (MTEs) for the Treatment of diffuse midline glioma (DMG) | Brain Tumors | Diffuse midline glioma (DMG) | |
| 2023 | $200,000.00 | St. Jude Children's Research Hospital | Dr. Elizabeth Stewart | Evaluation of PARP1 selective inhibitor AZD5305 in combination with DNA damaging agents in Ewing sarcoma | Solid and Bone Cancers | Ewing sarcoma | |
| 2023 | $200,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Meenakshi Hegde | Multi-center clinical testing of autologous HER2 CAR T cells and its synergy with surgical resection in recurrent ependymoma | Brain Tumors | Ependymoma | |
| 2023 | $100,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Philip Lupo | Outcomes and Health Risks among Individuals with Genetic Predispositions to Cancer: The ORIGen Study | |||
| 2023 | $200,000.00 | UCSF Benioff Children's Hospital | Dr. Ross Okimoto | Exploiting DNA repair mechanisms to overcome CIC-DUX4 sarcoma | Solid and Bone Cancers | Sarcoma | |
| 2022 | $150,000.00 | Children's Hospital of Philadelphia | Dr. John Maris | Developing a warehouse of peptide-centric CARs for neuroblastoma | Solid and Bone Cancers | Neuroblastoma | |
| 2022 | $206,500.00 | Children's Oncology Group | |||||
| 2022 | $150,000.00 | Memorial Sloan Kettering Cancer Center | Dr. Christopher Klebanoff | Therapeutic targeting of a recurrent fusion-derived "public" neoantigen expressed by pediatric desmoplastic small round cell tumors using T cell receptor (TCR) gene therapy | Solid and Bone Cancers | Sarcoma | |
| 2022 | $59,367.34 | Memorial Sloan Kettering Cancer Center | Dr. Brian Kushner | Phase II Study of Humanized 3F8 Anti-GD2 Monoclonal Antibody and GM-CSF in Patients with Refractory or Relapsed High-Risk neuroblastoma | Solid and Bone Cancer | Neuroblastoma | |
| 2022 | $150,000.00 | St. Jude Children's Research Hospital | Dr. Stephen Gottschalk | CD70-directed CAR T-cell therapy for the treatment of relapsed/refractory pediatric AML | Blood Cancer | Leukemia | Acute myeloid leukemia (AML) |
| 2022 | $150,000.00 | St. Jude Children's Research Hospital | Dr. Stephen Mack | The activity of combined epigenetic and immune checkpoint inhibition in H3K27me3 deficient brain tumors | Brain Tumors | ||
| 2022 | $150,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Robin Parihar | Development of a human natural killer cell immunotherapy against pediatric sarcomas | Solid and Bone Cancers | Sarcoma | |
| 2022 | $150,000.00 | UCSF Benioff Children's Hospital | Dr. Elliot Stieglitz | CLL-1 CAR-T cells for the treatment of JMML | Blood Cancer | Leukemia | Juvenile myelomonocytic leukemia (JMML) |
| 2022 | $150,000.00 | UCSF Benioff Children's Hospital | Dr. E. Alejandro Sweet-Cordero | Targeting the DNA damage response pathway to treat metastatic osteosarcoma | Solid and Bone Cancers | Osteosarcoma | |
| 2021 | $150,000.00 | Children's Hospital of Philadelphia | Dr. John Maris | Developing a warehouse of peptide-centric CARs for neuroblastoma | Solid and Bone Cancers | Neuroblastoma | |
| 2021 | $143,500.00 | Children's Oncology Group | |||||
| 2021 | $150,000.00 | Memorial Sloan Kettering Cancer Center | Dr. Christopher Klebanoff | Therapeutic targeting of a recurrent fusion-derived "public" neoantigen expressed by pediatric desmoplastic small round cell tumors using T cell receptor (TCR) gene therapy | Solid and Bone Cancers | Sarcoma | |
| 2021 | $50,000.00 | Seattle Children's Hospital/Fred Hutchinson Cancer Research Center | Dr. Nicholas Vitanza | Advanced molecular monitoring of CAR T cell therapy for diffuse midline gliomas | Brain Tumors | Diffuse midline gliomas (DMG) | |
| 2021 | $150,000.00 | St. Jude Children's Research Hospital | Dr. Jiyang Yu | Combination Therapy Targeting Hidden Drivers in MYC-driven Medulloblastoma | Brain Tumors | Medulloblastoma | |
| 2021 | $150,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Carl Allen | Testing Depletion of Pathogenic Cells in Langerhans cell histiocytosis | Blood Cancer | Langerhans cell histiocytosis | |
| 2021 | $150,000.00 | UCSF Benioff Children's Hospital | Dr. Kevin Shannon | Co-targeting Raf and MEK in Pediatric acute myeloid leukemia | Blood Cancer | Leukemia | Acute myeloid leukemia (AML) |
| 2020 | $100,000.00 | Children's Hospital of Philadelphia | Dr. Kathrin M. Bernt | Understanding mechanisms and developing therapies for MN1-driven leukemia | Blood Cancer | Leukemia | |
| 2020 | $150,500.00 | Children's Oncology Group | |||||
| 2020 | $100,000.00 | Dana-Farber Cancer Institute/Jimmy Fund | Dr. Rani George | Augmenting immune response in neuroblastoma | Solid and Bone Cancers | Neuroblastoma | |
| 2020 | $50,000.00 | Seattle Children's Hospital/Fred Hutchinson Cancer Research Center | Dr. Nicholas Vitanza | Advanced molecular monitoring of CAR T cell therapy for diffuse midline gliomas | Brain Tumors | Diffuse midline gliomas (DMG) | |
| 2020 | $100,000.00 | St. Jude Children's Research Hospital | Dr. Martine F Roussel | Targeting the p53 pathway in high risk pediatric atypical teratoid rhabdoid tumors | Solid and Bone Cancers | Rhabdoid Tumors | |
| 2020 | $100,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Robin Parihar | Development of a human natural killer cell immunotherapy against pediatric sarcomas | Solid and Bone Cancers | Sarcoma | |
| 2020 | $100,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Jason Yustein | Targeting PAK4 in high-risk rhabdomyosarcoma | Solid and Bone Cancers | Rhabdomyosarcoma | |
| 2020 | $100,000.00 | UCSF Benioff Children's Hospital | Dr. Ernesto Diaz-Flores | Exploiting therapeutic opportunities against high-risk leukemias harboring TP53 mutations | Blood Cancer | Leukemia | |
| 2019 | $150,000.00 | Children's Hospital of Philadelphia | Dr. Yael Mossé | Clinical Development of Next Generation ALK inhibitor lorlatinib for patients with ALK-driven neuroblastomas | Solid and Bone Cancers | Neuroblastoma | |
| 2019 | $200,000.00 | Children's Hospital of Philadelphia | Dr. Andrei Thomas-Tikhonenko | Novel chenoimmunotherapeutics for B-lymphoid childhood malignancies | Blood Cancer | Leukemia/Lymphoma | |
| 2019 | $143,500.00 | Children's Oncology Group | |||||
| 2019 | $200,000.00 | Dana-Farber Cancer Institute/Jimmy Fund | Dr. Brigit Knoechel | Targeting Galectin-9 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia | Blood Cancer | Leukemia / Lymphoma | |
| 2019 | $200,000.00 | Memorial Sloan Kettering Cancer Center | Dr. Michael Ortiz | A multi-center phase I study of codrituzumab in pediatric patients with relapsed or refractory glypican 3 (GPC3) expressing extra-cranial solid tumors | Solid and Bone Cancers | Hepatoblastoma, Wilms tumor, rhabdoid tumors, germ cell tumors | |
| 2019 | $100,000.00 | Seattle Children's Hospital/Fred Hutchinson Cancer Research Center | Dr. Marie Bleakley | Immunotherapy for Infant Leukemia - Extension Application | Blood Cancer | Leukemia | |
| 2019 | $200,000.00 | St. Jude Children's Research Hospital | Dr. Brandon Triplett | Allogeneic CD19-CAR T cells for ALL | Blood Cancer | Leukemia / Lymphoma | |
| 2019 | $200,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Stephen Mack | The activity of combined epigenetic and immune checkpoint inhibition in H3K27me3 deficient brain tumors | Brain Tumors | ||
| 2019 | $200,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Robin Parihar | Development of a human natural killer cell immunotherapy against pediatric sarcomas | Solid and Bone Cancers | Sarcoma | |
| 2019 | $200,000.00 | UCSF Benioff Children's Hospital | Dr. Clay Gustafson | Translating combinationtherapy of Aurora Kinase A inhibition with the targeted radiopharmaceutical 131IMIBG in neuroblastoma | Solid and Bone Cancers | Neuroblastoma | |
| 2018 | $274,300.00 | Children's Oncology Group | |||||
| 2018 | $200,000.00 | Dana-Farber Cancer Institute/Jimmy Fund | Dr. Steven DuBois | Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer | General Pediatric Cancer | ||
| 2018 | $200,000.00 | Memorial Sloan Kettering Cancer Center | Dr. Kim Kramer | Radioimmunotherapy with Intraventricular 131I-hu3F8 for CNS Malignancies | Brain Tumor | Medulloblastoma | |
| 2018 | $200,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Carl Allen | Redefining Standard of Care for Front-Line Therapy for Langerhans cell histiocytosis | Blood Cancer | Langerhans cell histiocytosis | |
| 2018 | $200,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Andras Heczey | T cells expressing an optimized Glypican-3-specific CAR for children with solid tumors | Solid and Bone Cancers | Hepatoblastoma, Wilms tumor, rhabdoid tumors, germ cell tumors | |
| 2018 | $200,000.00 | UCSF Benioff Children's Hospital | Dr. E. Alejandro Sweet-Cordero | Genome-informed therapy for osteosarcoma | Solid and Bone Cancers | Osteosarcoma | |
| 2017 | $200,000.00 | Children's Hospital of Philadelphia | Dr. David T. Teachey | Enhancing Chimeric Antigen Receptor efficacy by limiting toxicity | Blood Cancer | Leukemia | Acute Lymphoblastic Leukemia (ALL) |
| 2017 | $200,000.00 | Dana-Farber Cancer Institute/Jimmy Fund | Dr. Kimberly Stegmaier | Discovering Novel Drug Combinations with CDK4/6 Inhibitors in Pediatric Cancer | General Pediatric Cancer | ||
| 2017 | $200,000.00 | Memorial Sloan Kettering Cancer Center | Dr. Nai-Kong Cheung | Study of Biologic Correlates in a Phase I/II study of humanized 3F8 bispecific antibody (Hu3F8-BsAb) in patients with relapsed/refractory neuroblastoma, osteosarcoma, and other GD2(+) solid tumors | Solid and Bone Cancers | Neuroblastoma, Osteosarcoma | |
| 2017 | $200,000.00 | Memorial Sloan Kettering Cancer Center | Dr. Alex Kentsis | Control and therapy of genome integrity in medulloblastoma | Brain Tumors | Medulloblastoma | |
| 2017 | $200,000.00 | Seattle Children's Hospital/Fred Hutchinson Cancer Research Center | Dr. Marie Bleakley | Immunotherapy for Infant Leukemia | Blood Cancer | Leukemia | |
| 2017 | $200,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Meenakshi Hegde | Phase 1 trial of autologous HER2-CAR T cells after lymphodepletion for HER2-positive solid tumors in children | Solid and Bone Cancers | Osteosarcoma, gliomas, sarcomas | |
| 2017 | $185,221.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Leonid Metelitsa | Generation of cGMP grade antigen-presenting cells for NKT-cell expansion | Solid and Bone Cancers | Neuroblastoma | |
| 2017 | $200,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Cliona Rooney | VZV Vaccination to enhance the activity of GD2.CAR-modified, VZV-specific T-cells against neuroblastoma and osteosarcoma | Solid and Bone Cancers | Neuroblastoma & Osteosarcoma | |
| 2017 | $200,000.00 | UCSF Benioff Children's Hospital | Dr. Mignon Loh | Identifying Targeted Therapeutics in juvenile myelomonocytic leukemia | Blood Cancer | Leukemia | |
| 2016 | $200,000.00 | Children's Hospital of Philadelphia | Dr. Carolyn Felix | Ribavirin-Epigenetic Therapy Combinations to Combat MLL-R Infant ALL | Blood Cancer | Leukemia / Lymphoma | |
| 2016 | $2,200.00 | Children's Hospital of Philadelphia | Dr. Michael Hogarty | LCH-CLO Trial | Blood Cancer | Langerhans cell histiocytosis | |
| 2016 | $200,000.00 | Children's Hospital of Philadelphia | Dr. Yael Mossé | Clinical Development of Next Generation ALK inhibitor lorlatinib for patients with ALK-driven neuroblastomas | Solid and Bone Cancers | Neuroblastoma | |
| 2016 | $200,000.00 | Dana-Farber Cancer Institute/Jimmy Fund | Dr. Scott Armstrong | New combination therapies for MLL-rearranged Acute Lymphoblastic Leukemia | Blood Cancer | Leukemia / Lymphoma | |
| 2016 | $200,000.00 | Dana-Farber Cancer Institute/Jimmy Fund | Dr. Nicholas Haining | Discovering somatic mutations in cancer that cause resistance to immunotherapy | General Pediatric Cancer | ||
| 2016 | $200,000.00 | Memorial Sloan Kettering Cancer Center | Dr. Brian Kushner | Phase II Study of Humanized 3F8 Anti-GD2 Monoclonal Antibody and GM-CSF in Patients with Refractory or Relapsed High-Risk neuroblastoma | Solid and Bone Cancers | Neuroblastoma | |
| 2016 | $200,000.00 | St. Jude Children's Research Hospital | Dr. Sara Federico | A pilot induction regimen incorporating dinutuximab for the treatment of newly diagnosed high-risk neuroblastoma | Solid and Bone Cancers | Neuroblastoma | |
| 2016 | $200,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Carl Allen | Correlative Biology to Predict Response and Toxicity in Children Receiving Immunotherapy and Cytotoxic T Cell Therapy for Post- Transplant Lymphoproliferative Disease | Blood Cancer | ||
| 2016 | $200,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Ronald Bernardi | Combined inhibition of WEE1 and oncogenic receptor tyrosine kinases as a therapeutic strategy to overcome redundant mitotic checkpoint control in neuroblastoma | Solid and Bone Cancers | Neuroblastoma | |
| 2016 | $407,269.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Andras Heczey | T cells expressing an optimized Glypican-3- specific CAR for children with solid tumors | Solid and Bone Cancers | Hepatoblastoma, Wilms tumor, rhabdoid tumors, germ cell tumors | |
| 2016 | $200,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Ann Leen | Adoptive T-cell therapy for ALL targeting multiple tumor associated antigens | Blood Cancers | Leukemia | Acute Lymphoblastic Leukemia |
| 2016 | $200,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Jason Shohet | A Safety Pilot Study of High Risk Induction Chemotherapy for neuroblastoma without Prophylactic Administration of Myeloid Growth Factors (SPRING) | Solid and Bone Cancers | Neuroblastoma | |
| 2015 | $200,000.00 | Children's Hospital of Philadelphia | Dr. Yael Mossé | Preclinical and Clinical Development of Next Generation ALK Inhibitor, PF-06463922, or ALK driven neuroblastoma | Solid and Bone Cancers | Neuroblastoma | |
| 2015 | $150,000.00 | Children's Oncology Group | Dr. Michael LaQuaglia | Prospective study of outcomes after pulmonary metastectomy in patients with newly diagnosed or recurrent osteosarcoma and pulmonary metastasis | Solid and Bone Cancers | Osteosarcoma | |
| 2015 | $500,000.00 | Children's Oncology Group | Full payment for $4k per child enrolled in 2015 to COG's Phase 1 Clinical Trial Consortium. 2x the Federal Government's per child allocation | ||||
| 2015 | $200,000.00 | Memorial Sloan Kettering Cancer Center | Dr. Kim Kramer | A phase I study of convection-enhanced delivery of 124I-8H9 for patients with non-progressive diffuse pontine gliomas (DIPG) previously treated with external beam radiation therapy | Brain Tumors | Diffuse intrinsic pontine glioma (DIPG) | |
| 2015 | $200,000.00 | Memorial Sloan Kettering Cancer Center | Dr. Shakeel Modak | The development and preclinical validation of site-specifically radiolabeled hu3F8 for PET Imaging and radioimmunotherapy of neuroblastoma | Solid and Bone Cancers | Neuroblastoma | |
| 2015 | $50,000.00 | Memorial Sloan Kettering Cancer Center | Dr. Shakeel Modak | Targeting Pediatric Solid Tumors: A Pilot Study of RadioImmuno-PET Imaging using I-Humanized 3F8 | Solid and Bone Cancers | Neuroblastoma | |
| 2015 | $100,000.00 | St. Jude Children's Research Hospital | Dr. Jeffrey Rubnitz | Pilot study of microtransplantation in pediatric patients with refractory or relapsed acute myeloid leukemia | Blood Cancer | Leukemia | |
| 2015 | $200,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Nabil Ahmed | Adoptive Immunotherapy for Pediatric Sarcoma | Solid and Bone Cancers | Sarcoma | |
| 2015 | $200,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Carl Allen | Redefining Standard of Care for Front-line Therapy for Langerhans cell histiocytosis (LCH) | Blood Cancer | Langerhans cell histiocytosis | |
| 2015 | $200,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Donald Parsons | Evaluating the Impact of Tumor Heterogeneity and Clonal Evolution on Clinical Genomic Testing for Pediatric Solid Tumor Patients | Solid and Bone Cancers | ||
| 2015 | $100,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Jason Shohet | Characterization and targeting of neuroblastoma Cancer Stem Cells (CSCs) | Solid and Bone Cancers | Neuroblastoma | |
| 2014 | $200,000.00 | Children's Hospital of Philadelphia | Dr. Richard Aplenc | Chimeric antigen receptor T cell immunotherapy for pediatric acute myeloid leukemia | Blood Cancer | Leukemia | Acute myeloid leukemia (AML) |
| 2014 | $200,000.00 | Children's Hospital of Philadelphia | Dr. John Maris | Identifying novel drug combinations for neuroblastoma | Solid and Bone Cancers | Neuroblastoma | |
| 2014 | $150,000.00 | Children's Oncology Group | Dr. Michael LaQuaglia | Comprehensive national study to standardize treatments after pulmonary metastectomy in patients with newly diagnosed or recurrent osteosarcoma and pulmonary metastasis. *Second year of 3-year project totaling $450,000 | Solid and Bone Cancers | Osteosarcoma | |
| 2014 | $700,000.00 | Children's Oncology Group | |||||
| 2014 | $100,000.00 | Dana-Farber Cancer Institute/Jimmy Fund | Dr. Jerome Ritz/Dr. Glenn Dranoff | A Phase I Study of irradiated GM-CSF secreting autologous neuroblastoma cell vaccine (GVAX) for relapsed or refractory neuroblastoma | Solid and Bone Cancers | Neuroblastoma | |
| 2014 | $100,000.00 | Memorial Sloan Kettering Cancer Center | Dr. Nai-Kong Cheung | Bispecific T-Cell Engaging (BiTE) Antibody to Target neuroblastoma | Solid and Bone Cancers | Neuroblastoma | |
| 2014 | $150,000.00 | Memorial Sloan Kettering Cancer Center | Dr. Brian Kushner | Bivalent vaccine plus beta-glucan for high-risk neuroblastoma in first remission | Solid and Bone Cancers | Neuroblastoma | |
| 2014 | $200,000.00 | Memorial Sloan Kettering Cancer Center | Dr. Shakeel Modak | Targeting pediatric solid tumors: A pilot study of Radiolmmuno-PET imaging using 124I-Humanized 3F8 | Solid and Bone Cancers | Neuroblastoma | |
| 2014 | $100,000.00 | St. Jude Children's Research Hospital | Dr. Charles Mullighan | Identifying novel drivers and childhood acute lymphoblastic leukemia disease and resistance | Blood Cancer | Leukemia / Lymphoma | |
| 2014 | $100,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Stephen Gottschalk | IL13Ra2-CAR T-cell therapy for pediatric high grade glioma | Brain Tumors | High-grade glioma | |
| 2014 | $100,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Peter Zage | A Phase I Study of vandetanib (CaprelsaTM) in combination with 13-cis-retinoic acid in children with relapsed or refractory solid tumors | Solid and Bone Cancers | ||
| 2013 | $100,000.00 | Children's Hospital of Philadelphia | Dr. Kim Nichols | Novel cell-based therapy for b cell leukemias and lymphomas | Blood Cancer | Leukemia / Lymphoma | |
| 2013 | $100,000.00 | Children's Hospital of Philadelphia | Dr. Andrei Thomas-Tikhonenko | Decreasing resistance to chemotherapies in pediatric lymphomas, and decreasing sensitivities and effects related to the chemotherapy drug Doxorubicin | Blood Cancer | Lymphoma | |
| 2013 | $150,000.00 | Children's Oncology Group | Dr. Michael LaQuaglia | Comprehensive national study to standardize treatments after pulmonary metastectomy in patients with newly diagnosed or recurrent osteosarcoma and pulmonary metastasis. *First year of 3-year project totaling $450,000 | Solid and Bone Cancers | Osteosarcoma | |
| 2013 | $352,000.00 | Children's Oncology Group | Matching federal funds per child enrolled in Phase I clinical trials | ||||
| 2013 | $100,000.00 | Dana-Farber Cancer Institute/Jimmy Fund | Dr. Kimberly Stegmaier | New treatments for neuroblastoma by targeting the Epigenome | Solid and Bone Cancers | Neuroblastoma | |
| 2013 | $100,000.00 | Memorial Sloan Kettering Cancer Center | Dr. Nai-Kong Cheung | Retargeting t cells using bispecific antibody against receptor Tyrosine Kinase-like orphan receptors 2 (Ror2) in solid tumors | Solid and Bone Cancers | ||
| 2013 | $100,000.00 | St. Jude Children's Research Hospital | Dr. Hiroto Inaba | Genetic characterization and therapeutic targeting of pediatric mixed phenotype acute leukemia | Blood Cancer | Leukemia | |
| 2013 | $100,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Stacey Berg | Phase I trial of Sgt-53, a novel nanoparticle therapy, for children with refractory or recurrent solid tumors | Solid and Bone Cancers | ||
| 2013 | $100,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Leonid Metelitsa | Phase I clinical trial of a novel immune therapy using dual-specific Nkt cells for children with neuroblastoma | Solid and Bone Cancers | Neuroblastoma | |
| 2012 | $100,000.00 | Children's Hospital of Philadelphia | Dr. Edward Attiyeh | Xpo1 Inhibition in neuroblastoma | Solid and Bone Cancers | Neuroblastoma | |
| 2012 | $100,000.00 | Children's Hospital of Philadelphia | Dr. Craig Bassing | Targeting Bcl11b Haploin sufficient lymphoid tumors 6 | Blood Cancer | Lymphoma | |
| 2012 | $350,000.00 | Children's Oncology Group | Matching federal funds per child enrolled in Phase I clinical trials | ||||
| 2012 | $100,000.00 | Dana-Farber Cancer Institute/Jimmy Fund | Dr. Barbara Degar/Dr. Carlos Rodriguez-Galindo | Phase II study of clofarabine in refractory Langerhans cell histiocytosis | Blood Cancer | Langerhans cell histiocytosis | |
| 2012 | $100,000.00 | Dana-Farber Cancer Institute/Jimmy Fund | Dr. Roberts | Targeting of Cdk4 signaling in pediatric Rhabdoid tumors | Solid and Bone Cancers | Rhabdoid Tumor | |
| 2012 | $100,000.00 | Dana-Farber Cancer Institute/Jimmy Fund | Dr. Suzanne Shusterman | Csf producing whole tumor vaccine for neurblastoma | Solid and Bone Cancers | Neuroblastoma | |
| 2012 | $100,000.00 | Memorial Sloan Kettering Cancer Center | Dr. Nai-Kong Cheung | Dual specific human monoclonal antibody targeting IGF-I and IGF-II for pediatric cancers | Solid and Bone Cancers | Neuroblastoma | |
| 2012 | $100,000.00 | Memorial Sloan Kettering Cancer Center | Dr. Kim Kramer | Delivery of 124-I-8h9 non-progressive diffuse Pontine Gliomas | Brain Tumors | Diffuse intrinsic pontine glioma (DIPG) | |
| 2012 | $100,000.00 | St. Jude Children's Research Hospital | Dr. Wayne Furman | Hu14.18322a + Multi-Modality treatment for neuroblastoma | Solid and Bone Cancers | Neuroblastoma | |
| 2012 | $100,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Stephen Gottschalk | Fap-targeted t cell therapy for osteosarcoma | Solid and Bone Cancers | Osteosarcoma | |
| 2011 | $100,000.00 | Children's Hospital of Philadelphia | Dr. John Maris | Molecular oncology for pediatric cancers | Solid and Bone Cancers | Neuroblastoma | |
| 2011 | $100,000.00 | Children's Hospital of Philadelphia | Dr. M. Weiss | Modeling juvenile myelomonocytic leukemia patient Ips cells | Blood Cancer | Leukemia | |
| 2011 | $100,000.00 | Dana-Farber Cancer Institute/Jimmy Fund | Dr. George | Development of dendritic call vaccine against Alk-Positive | Solid and Bone Cancers | Neuroblastoma and others | |
| 2011 | $100,000.00 | Dana-Farber Cancer Institute/Jimmy Fund | Dr. Kimberly Stegmaier | Validation of fak therapeutic target in Ewings sarcoma | Solid and Bone Cancers | Ewings sarcoma | |
| 2011 | $100,000.00 | Memorial Sloan Kettering Cancer Center | Dr. Nai-Kong Cheung | A safe, potent Saponin adjuvant for Gd2 conjugated vaccine for neuroblastoma | Solid and Bone Cancers | Neuroblastoma | |
| 2011 | $100,000.00 | Memorial Sloan Kettering Cancer Center | Dr. Nai-Kong Cheung | Bite Therapy | Solid and Bone Cancers | Neuroblastoma | |
| 2011 | $100,000.00 | Memorial Sloan Kettering Cancer Center | Dr. Nai-Kong Cheung | Bite Therapy | Solid and Bone Cancers | Neuroblastoma | |
| 2011 | $25,000.00 | Memorial Sloan Kettering Cancer Center | Dr. Nai-Kong Cheung | Bite Therapy | Solid and Bone Cancers | Neuroblastoma | |
| 2011 | $100,000.00 | Memorial Sloan Kettering Cancer Center | Dr. Michael LaQuaglia | Phase I trial of Hepatic Artery Infusion/neuroblastoma tumors in the liver | Solid and Bone Cancers | Neuroblastoma | |
| 2011 | $100,000.00 | St. Jude Children's Research Hospital | Dr. Richard Gilbertson | Rapid and accurate diagnosis of Medolloblastoma subtypes in trials | Brain Tumors | Medolloblastoma | |
| 2011 | $100,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Leonid Metelitsa | Immunotherapy of neuroblastoma with dual-specific Nkt cells | Solid and Bone Cancers | Neuroblastoma | |
| 2011 | $100,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Jed Nuchtern | Genomic anatomy of chemotherapy-resistant neuroblastoma | Solid and Bone Cancers | Neuroblastoma | |
| 2010 | $100,000.00 | Children's Hospital of Philadelphia | Dr. Stephen Grupp | Engineered T Cell Therapy For Recurrent neuroblastoma & B Cell Malignancies | Solid and Bone Cancers | Neuroblastoma | |
| 2010 | $100,000.00 | Children's Hospital of Philadelphia | Dr. Michael Hogarty | Sirna based Kimome screen to id Mcl1 antagonists for resistant Tumors | |||
| 2010 | $100,000.00 | Memorial Sloan Kettering Cancer Center | Dr. Nai-Kong Cheung | Bite Therapy, 2nd round of funding | Solid and Bone Cancers | Neuroblastoma | |
| 2010 | $100,000.00 | St. Jude Children's Research Hospital | Dr. Deepa Bhojwani | CD-20 targeted immunotherapy for relapsed childhood neuroblastoma | Solid and Bone Cancers | Neuroblastoma | |
| 2010 | $100,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Jason Shohet | Therapy for relapsed neuroblastoma. P13k/Aktm tor pathway inhibition | Solid and Bone Cancers | Neuroblastoma | |
| 2010 | $100,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Jack Meng-Fen Su | Therapy efficacy study for newly diagnosed brainstem gliomas | Brain Tumors | Diffuse intrinsic pontine glioma (DIPG) | |
| 2009 | $100,000.00 | Memorial Sloan Kettering Cancer Center | Dr. Nai-Kong Cheung | Bite Therapy | Solid and Bone Cancers | Neuroblastoma | |
| 2009 | $150,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Chrystal Louis | A phase I/II study using allogenic tumor cell vaccination with oral metronomic cytoxan in patients with high-risk neuroblastoma | Solid and Bone Cancers | Neuroblastoma | |
| 2009 | $85,000.00 | Texas Children's Cancer Center/Baylor College of Medicine | Dr. Karen Rabin | Novel therapy using JAK-STAT pathway inhibitors in childhood leukemias | Blood Cancer | Leukemia | |
| 2008 | $400,000.00 | Memorial Sloan Kettering Cancer Center | Dr. Nai-Kong Cheung | Hu3f8 antibody treatment for neuroblastoma | Solid and Bone Cancers | Neuroblastoma |
GET INVOLVED
Ready to Take Action?
Funding a single study could result in thousands of children’s lives saved.